Table 1.
Breast tumor characteristics of 7,797 affected BRCA1 mutation carriers and 4,330 affected BRCA2 mutation carriers a
| BRCA1 mutation carriers | BRCA2 mutation carriers | |||||
|---|---|---|---|---|---|---|
| Yes, n (%) | No, n (%) | Unknown status | Yes, n (%) | No, n (%) | Unknown status | |
| Predictive markers | ||||||
| ER-positive | 819 (24) | 2,639 (76) | 4,339 | 1,490 (77) | 434 (23) | 2,406 |
| PR-positive | 662 (21) | 2,485 (79) | 4,650 | 1,099 (65) | 591 (35) | 2,640 |
| HER2-positive | 182 (9) | 1,816 (91) | 5799 | 121 (13) | 847 (87) | 3,362 |
| Non-TN | 580 (31) | 1,310 (69) | 5907 | 760 (85) | 136 (15) | 3,434 |
| Morphology | 3,789 | 2,087 | ||||
| Ductal | 3,159 (82) | 1,770 (79) | ||||
| Lobular | 89 (2) | 188 (8) | ||||
| Medullary | 290 (6) | 39 (2) | ||||
| Other | 470 (10) | 246 (11) | ||||
| Grade | 4,645 | 3,840 | ||||
| Grade 1 | 81 (3) | 113 (7) | ||||
| Grade 2 | 574 (18) | 700 (42) | ||||
| Grade 3 | 2,497 (79) | 839 (51) | ||||
| Nodal involvement | 1,103 (33) | 2,274 (67) | 4,420 | 804 (43) | 1,068 (57) | 2,458 |
| Stage | 5,991 | 3,382 | ||||
| Stage 0b | 65 (4) | 121 (13) | ||||
| Stage 1 | 825 (46) | 327 (35) | ||||
| Stage 2 | 772 (43) | 390 (41) | ||||
| Stage 3 | 127 (7) | 96 (10) | ||||
| Stage 4 | 17 (1) | 14 (1) | ||||
aER, Estrogen receptor positive; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; TN, Triple-negative. bCarcinoma in situ.